Incidence and Risk Factors of COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unit-A Monocentric Retrospective Observational Study.

Gregoire, Emilien; Pirotte, Benoit François; Moerman, Filip; Altdorfer, Antoine; Gaspard, Laura; Firre, Eric; Moonen, Martial; Fraipont, Vincent; ERNST, Marie; DARCIS, Gilles

doi:10.3390/pathogens10111370

Article (Scientific journals)

Incidence and Risk Factors of COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unit-A Monocentric Retrospective Observational Study.

Gregoire, Emilien; Pirotte, Benoit François; Moerman, Filip et al.

2021 • In Pathogens (Basel, Switzerland), 10 (11)

Peer reviewed

Permalink
https://hdl.handle.net/2268/266056

DOI
10.3390/pathogens10111370

PubMed
34832526

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2021-publication-pathogens-10-01370-v2.pdf

Publisher postprint (1.01 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

COVID-19-associated pulmonary aspergillosis (CAPA); bronchoalveolar lavage (BAL); coronavirus disease 2019 (COVID-19); galactomannan (GM); intensive care unit (ICU); invasive pulmonary aspergillosis (IPA)

Abstract :

[en] Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is an increasingly recognized complication of COVID-19 and is associated with significant over-mortality. We performed a retrospective monocentric study in patients admitted to the intensive care unit (ICU) for respiratory insufficiency due to COVID-19 from March to December 2020, in order to evaluate the incidence of CAPA and the associated risk factors. We also analysed the diagnostic approach used in our medical centre for CAPA diagnosis. We defined CAPA using recently proposed consensus definitions based on clinical, radiological and microbiological criteria. Probable cases of CAPA occurred in 9 out of 141 patients included in the analysis (6.4%). All cases were diagnosed during the second wave of the pandemic. We observed a significantly higher realization rate of bronchoalveolar lavage (BAL) (51.1% vs. 28.6%, p = 0.01) and Aspergillus testing (through galactomannan, culture, PCR) on BAL samples during the second wave (p < 0.0001). The testing for Aspergillus in patients meeting the clinical and radiological criteria of CAPA increased between the two waves (p < 0.0001). In conclusion, we reported a low but likely underestimated incidence of CAPA in our population. A greater awareness and more systematic testing for Aspergillus are necessary to assess the real incidence and characteristics of CAPA.

Disciplines :

Immunology & infectious disease

Author, co-author :

Gregoire, Emilien

Pirotte, Benoit François

Moerman, Filip

Altdorfer, Antoine

Gaspard, Laura

Firre, Eric

Moonen, Martial

Fraipont, Vincent

ERNST, Marie ; Centre Hospitalier Universitaire de Liège - CHU > Département de gestion des systèmes d'informations (GSI) > Secteur d'appui à la recherche clinique et biostatistique

DARCIS, Gilles ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses - médecine interne

Language :

English

Title :

Incidence and Risk Factors of COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unit-A Monocentric Retrospective Observational Study.

Publication date :

2021

Journal title :

Pathogens (Basel, Switzerland)

ISSN :

2076-0817

eISSN :

2076-0817

Volume :

Issue :

Peer reviewed :

Peer reviewed

Available on ORBi :

since 14 December 2021

Statistics

Number of views

68 (12 by ULiège)

Number of downloads

4 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Blot, S.I.; Taccone, F.S.; Van Den Abeele, A.M.; Bulpa, P.; Meersseman, W.; Brusselaers, N.; Dimopoulos, G.; Paiva, J.A.; Misset, B.; Rello, J.; et al. A Clinical Algorithm to Diagnose Invasive Pulmonary Aspergillosis in Critically Ill Patients. Am. J. Respir. Crit. Care Med. 2012, 186, 56–64. https://doi.org/10.1164/rccm.201111-1978OC.
Schauwvlieghe, A.F.; Rijnders, B.J.; Philips, N.; Verwijs, R.; Vanderbeke, L.; Van Tienen, C.; Lagrou, K.; Verweij, P.E.; Van de Veerdonk, F.L.; Gommers, D.; et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study. Lancet Respir. Med. 2018, 6, 782–792. https://doi.org/10.1016/S2213-2600(18)30274-1.
Verweij, P.E.; Rijnders, B.J.A.; Brüggemann, R.J.M.; Azoulay, E.; Bassetti, M.; Blot, S.; Calandra, T.; Clancy, C.J.; Cornely, O.A.; Chiller, T.; et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: An expert opinion. Intensive Care Med. 2020, 46, 1524–1535. https://doi.org/10.1007/s00134-020-06091-6.
Schwartz, I.; Friedman, D.; Zapernick, L.; Dingle, T.; Lee, N.; Sligl, W.; Zelyas, N.; Smith, S.W. High Rates of Influenza-Associated Invasive Pulmonary Aspergillosis May Not Be Universal: A Retrospective Cohort Study from Alberta, Canada. Clin. Infect. Dis. 2020, 71, 1760–1763. https://doi.org/10.1093/CID/CIAA007.
Huang, L.; Zhang, N.; Huang, X.; Xiong, S.; Feng, Y.; Zhang, Y.; Li, M.; Zhan, Q. Invasive pulmonary aspergillosis in patients with influenza infection: A retrospective study and review of the literature. Clin. Respir. J. 2019, 13, 202– 211. https://doi.org/10.1111/CRJ.12995.
Ku, Y.; Chan, K.; Yang, C.; Tan, C.; Chuang, Y.; Yu, W. Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections. J. Formos. Med. Assoc. 2017, 116, 660–670. https://doi.org/10.1016/J.JFMA.2017.06.002.
Pasquier, G.; Bounhiol, A.; Robert Gangneux, F.; Zahar, J.; Gangneux, J.P.; Novara, A.; Bougnoux, M.; Dannaoui, E. A review of significance of Aspergillus detection in airways of ICU COVID‐19 patients. Mycoses 2021. https://doi.org/10.1111/myc.13341.
Wauters, J.; Baar, I.; Meersseman, P.; Meersseman, W.; Dams, K.; De Paep, R.; Lagrou, K.; Wilmer, A.; Jorens, P.; Hermans, G. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: A retrospective study. Intensive Care Med. 2012, 38, 1761–1768. https://doi.org/10.1007/S00134-012-2673-2.
Van De Veerdonk, F.L.; Kolwijck, E.; Lestrade, P.P.A.; Hodiamont, C.J.; Rijnders, B.J.A.; Van Paassen, J.; Haas, P.J.; Dos Santos, C.O.; Kampinga, G.A.; Bergmans, D.C.; et al. Influenza-associated aspergillosis in critically ill patients. Am. J. Respir. Crit. Care Med. 2017, 196, 524–527. https://doi.org/10.1164/rccm.201612-2540LE.
Wu, Z.; McGoogan, J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA J. Am. Med. Assoc. 2020, 323, 1239–1242. https://doi.org/10.1001/jama.2020.2648.
Stokes, E.K.; Zambrano, L.D.; Anderson, K.N.; Marder, E.P.; Raz, K.M.; Felix, S.E.B.; Tie, Y.; Fullerton, K.E. Coronavirus Disease 2019 Case Surveillance—United States, January 22–May 30, 2020. MMWR. Morb. Mortal. Wkly. Rep. 2020, 69, 759–765. https://doi.org/10.15585/mmwr.mm6924e2.
Thompson, G.R.; Cornely, O.A.; Pappas, P.G.; Patterson, T.F.; Hoenigl, M.; Jenks, J.D.; Clancy, C.J.; Nguyen, M.H. Invasive aspergillosis as an under-recognized superinfection in COVID-19. Open Forum Infect. Dis. 2020, 7. https://doi.org/10.1093/ofid/ofaa242.
Arastehfar, A.; Carvalho, A.; van de Veerdonk, F.L.; Jenks, J.D.; Koehler, P.; Krause, R.; Cornely, O.A.; SPerlin, D.; Lass-Flörl, C.; Hoenigl, M. COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment. J. Fungi Basel Switz. 2020, 6, 1–17. https://doi.org/10.3390/JOF6020091.
Horby, P.; Lim, W.; Emberson, J.; Mafham, M.; Bell, J.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; et al. Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2021, 384, 693–704. https://doi.org/10.1056/NEJMOA2021436.
Lionakis, M.S.; Kontoyiannis, D.P. Glucocorticoids and invasive fungal infections. Lancet 2003, 362, 1828–1838. https://doi.org/10.1016/S0140-6736(03)14904-5.
Lewis, R.; Kontoyiannis, D. Invasive aspergillosis in glucocorticoid-treated patients. Med. Mycol. 2009, 47 (Suppl. S1). https://doi.org/10.1080/13693780802227159.
Russell, C.; Millar, J.; Baillie, J. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet Lond. Engl. 2020, 395, 473–475. https://doi.org/10.1016/S0140-6736(20)30317-2.
Alanio, A.; Dellière, S.; Fodil, S.; Bretagne, S.; Mégarbane, B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir. Med. 2020, 8, e48–e49. https://doi.org/10.1016/S2213-2600(20)30237-X.
Koehler, P.; Cornely, O.A.; Böttiger, B.W.; Dusse, F.; Eichenauer, D.A.; Fuchs, F.; Hallek, M.; Jung, N.; Klein, F.; Persigehl, T.; et al. COVID-19 associated pulmonary aspergillosis. Mycoses 2020, 63, 528–534. https://doi.org/10.1111/myc.13096.
Rutsaert, L.; Steinfort, N.; Van Hunsel, T.; Bomans, P.; Naesens, R.; Mertes, H.; Dits, H.; Van Regenmortel, N. COVID-19-associated invasive pulmonary aspergillosis. Ann. Intensive Care 2020, 10. https://doi.org/10.1186/s13613-020-00686-4.
Schein, F.; Munoz-Pons, H.; Mahinc, C.; Grange, R.; Cathébras, P.; Flori, P. Fatal aspergillosis complicating severe SARS-CoV-2 infection: A case report. J. Mycol. Med. 2020, 30, 101039. https://doi.org/10.1016/j.mycmed.2020.101039.
Van Arkel, A.L.E.; Rijpstra, T.A.; Belderbos, H.N.A.; van Wijngaarden, P.; Verweij, P.E.; Bentvelsen, R.G. COVID-19-associated pulmonary aspergillosis. Am. J. Respir. Crit. Care Med. 2020, 202, 132–135. https://doi.org/10.1164/rccm.202004-1038LE.
Lamoth, F.; Lewis, R.E.; Walsh, T.J.; Kontoyiannis, D.P. Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): A comparison with influenza associated aspergillosis (IAPA). J. Infect. Dis. 2021. https://doi.org/10.1093/infdis/jiab163.
Bartoletti, M.; Pascale, R.; Cricca, M.; Rinaldi, M.; Maccaro, A.; Bussini, L.; Fornaro, G.; Tonetti, T.; Pizzilli, G.; Francalanci, E.; et al. Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study. Clin. Infect. Dis. 2020. https://doi.org/10.1093/cid/ciaa1065.
White, P.L.; Dhillon, R.; Cordey, A.; Hughes, H.; Faggian, F.; Soni, S.; Pandey, M.; Whitaker, H.; May, A.; Morgan, M.; et al. A National Strategy to Diagnose Coronavirus Disease 2019–Associated Invasive Fungal Disease in the Intensive Care Unit. Clin. Infect. Dis. 2021. https://doi.org/10.1093/cid/ciaa1298.
Koehler, P.; Salmanton-García, J.; Gräfe, S.K.; Koehler, F.C.; Mellinghoff, S.C.; Seidel, D.; Steinbach, A.; Cornely, O.A. Baseline predictors influencing the prognosis of invasive aspergillosis in adults. Mycoses 2019, 62, 651–658. https://doi.org/10.1111/MYC.12926.
Apostolopoulou, A.; Esquer Garrigos, Z.; Vijayvargiya, P.; Lerner, A.; Farmakiotis, D Invasive Pulmonary Aspergillosis in Patients with SARS-CoV-2 Infection: A Systematic Review of the Literature. Diagnostics Basel Switz. 2020, 10. https://doi.org/10.3390/DIAGNOSTICS10100807.
Singh, S.; Verma, N.; Kanaujia, R.; Chakrabarti, A.; Rudramurthy, S. Mortality in critically ill patients with coronavirus disease 2019-associated pulmonary aspergillosis: A systematic review and meta-analysis. Mycoses 2021. https://doi.org/10.1111/MYC.13328.
Cox, M.J.; Loman, N.; Bogaert, D.; O’Grady, J. Co-infections: Potentially lethal and unexplored in COVID-19. Lancet. Microbe 2020, 1, e11. https://doi.org/10.1016/S2666-5247(20)30009-4.
Jenks, J.D.; Nam, H.; Hoenigl, M. Invasive aspergillosis in critically ill patients: Review of definitions and diagnostic approaches. Mycoses 2021, 64, 1002–1014. https://doi.org/10.1111/MYC.13274.
De Pauw, B.; Walsh, T.J.; Donnelly, J.P.; Stevens, D.A.; Edwards, J.E.; Calandra, T.; Pappas, P.G.; Maertens, J.; Lortholary, O.; Kauffman, C.A.; et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008, 46, 1813–1821. https://doi.org/10.1086/588660.
Wahidi, M.M.; Shojaee, S.; Lamb, C.R.; Ost, D.; Maldonado, F.; Eapen, G.; Caroff, D.A.; Stevens, M.P.; Ouellette, D.R.; Lilly, C.; et al. The Use of Bronchoscopy During the Coronavirus Disease 2019 Pandemic: CHEST/AABIP Guideline and Expert Panel Report. Chest 2020, 158, 1268–1281. https://doi.org/10.1016/J.CHEST.2020.04.036.
Koehler, P.; Bassetti, M.; Chakrabarti, A.; Chen, S.C.A.; Colombo, A.L.; Hoenigl, M.; Klimko, N.; Lass-Flörl, C.; Oladele, R.O.; Vinh, D.C.; et al. Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect. Dis. 2021, 21, e149–e162. https://doi.org/10.1016/S1473-3099(20)30847-1.
Dellière, S.; Dudoignon, E.; Fodil, S.; Voicu, S.; Collet, M.; Oillic, P.; Salmona, M.; Dépret, F.; Ghelfenstein-Ferreira, T.; Plaud, B.; et al. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: A French multicentric retrospective cohort. Clin. Microbiol. Infect. 2020, 27, 790.e1–790.e5. https://doi.org/10.1016/J.CMI.2020.12.005.
Prattes, J.; Wauters, J.; Giacobbe, D.; Lagrou, K.; Hoenigl, M. Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: Results from a European confederation of medical mycology registry. Intensive Care Med. 2021, 47, 1158–1160. https://doi.org/10.1007/S00134-021-06471-6.
Mitaka, H.; Kuno, T.; Takagi, H.; Patrawalla, P. Incidence and mortality of COVID-19-associated pulmonary aspergillosis: A systematic review and meta-analysis. Mycoses 2021, 64, 993–1001. https://doi.org/10.1111/MYC.13292.